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Background: Interleukin-12 (IL-12) based radiosensitization is an effective way of tumor treatment. Local cytokine
production, without systemic shedding, might provide clinical benefit in radiation treatment of sarcomas. Therefore,
the aim was to stimulate intratumoral IL-12 production by gene electrotransfer of plasmid coding for mouse IL-12
(mIL-12) into the tumors, in order to explore its radiosensitizing effect after single or multiple intratumoral gene
electrotransfer.
Methods: Solid SA-1 fibrosarcoma tumors, on the back of A/J mice, were treated intratumorally by mIL-12 gene
electrotransfer and 24 h later irradiated with a single dose. Treatment effectiveness was measured by tumor growth
delay and local tumor control assay (TCD50 assay). With respect to therapeutic index, skin reaction in the radiation
field was scored. The tumor and serum concentrations of cytokines mIL-12 and mouse interferon γ (mIFNγ) were
measured. Besides single, also multiple intratumoral mIL-12 gene electrotransfer before and after tumor irradiation
was evaluated.
Results: Single intratumoral mIL-12 gene electrotransfer resulted in increased intratumoral but not serum mIL-12
and mIFNγ concentrations, and had good antitumor (7.1% tumor cures) and radiosensitizing effect (21.4% tumor
cures). Combined treatment resulted in the radiation dose-modifying factor of 2.16. Multiple mIL-12 gene
electrotransfer had an even more pronounced antitumor (50% tumor cures) and radiosensitizing (86.7% tumor
cures) effect.
Conclusions: Single or multiple intratumoral mIL-12 gene electrotransfer resulted in increased intratumoral mIL-12
and mIFNγ cytokine level, and may provide an efficient treatment modality for soft tissue sarcoma as single or
adjuvant therapy to tumor irradiation.
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Novel therapeutic approaches, such as gene therapy,
often complement established ones: surgery, chemother-
apy or radiotherapy. Cytokines, such as tumor necrosis
factor (TNF-α), interleukins (IL-2, IL-12) and interferons
(IFN-α, IFN-β, IFN-γ), as recombinant molecules have
already proved effective for radiosensitization in preclin-
ical studies [1,2]. Their clinical use, however, has been
hampered by toxic systemic peak concentrations during
repetitive intravenous administration [1,3,4]. A new
method of such tumor radiosensitization is gene therapy* Correspondence: gsersa@onko-i.si
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reproduction in any medium, provided the orwith plasmids coding for cytokines, the advantage being
their sustained and controlled release [5].
One of the immunostimulatory cytokines with a good
antitumor and radiosensitizing effect is IL-12 [6]. It exhi-
bits antitumor effects that can be ascribed to the stimula-
tion of an immune response with augmented natural killer
cell and cytotoxic T cell activity and also to anti-
angiogenic effects [7]. Possible mechanisms of IL-12 radio-
sensitization are enhanced tumor antigen presentation
due to radiation induced apoptosis [8], anti-angiogenic
effects [9], and the production of radiosensitizer nitric
oxide [10]. The prevailing mechanism of radiosensitiza-
tion, however, is not clear and it might be influenced by
factors such as tumor type and the timing of the therapy.
The radiosensitizing effect of IL-12 has already beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with IL-12 performed with viral [8,9,11-16] and non-viral
gene transfer [17-19]; in combination with tumor irradi-
ation, a synergistic antitumor effect on local tumor growth
and distant metastases has been demonstrated. Gene elec-
trotransfer, utilizing the application of electric pulses to the
tissue for naked plasmid DNA transfer into the cells [20-
22] is a safe, non-toxic transfection method as efficient as
viral vectors. IL-12 gene electrotransfer can be performed
either intratumorally, with a predominantly local effect, or
into the muscle, with a systemic effect on primary tumors
and metastases [20,21,23,24]. The systemic effectiveness of
intramuscular IL-12 gene electrotransfer, with a high tumor
cure rate, has been demonstrated in subcutaneous murine
LPB and SA-1 sarcomas, as well as in induced SA-1 lung
metastases. In addition, in both tumor models, systemic re-
lease of IL-12 had a good radiosensitizing effect [17]. Sarco-
mas are a specific clinical situation in which tumor
irradiation alone cannot provide suitable local control of
larger, unresectable tumors [25-27]. Combining irradiation
with intratumoral IL-12 gene electrotransfer in order to ob-
tain a local radiosensitizing effect could thus be beneficial
for the treatment of bulky sarcomas.
Our study therefore explores the potential radiosensitizing
effectiveness of mIL-12 plasmid electrotransfer to sarcoma
tumors. Tumor and serum concentrations of cytokines
mIL-12 and mIFNγ were determined, as well as antitumor
effectiveness, degree of tumor radiosensitization and skin
reaction in the irradiation field. In addition to single, aTable 1 Antitumor effectiveness of single mIL-12 gene electro
sarcoma
Therapeutic group N DT (days; AM ± SE)*
Control 12 1.7 ± 0.2
EP 13 4.2 ± 0.6
dsRed 12 3.1 ± 0.3
EGT dsRed 14 5.3 ± 0.9
mIL-12 13 3.1 ± 0.4
EGT mIL12 14 20.0 ± 3.0 ‡
IR 13 5.4 ± 0.9
EP + IR 14 14.4 ± 4.2 ‡
dsRed + IR 9 5.3 ± 1.1
EGT dsRed + IR 11 9.3 ± 1.9
mIL-12 + IR 13 10.7 ± 1.7
EGT mIL-12 + IR 14 32.6 ± 4.3 ‡§
Therapeutic groups: 10 Gy single dose irradiation (IR), electrical pulse application al
plasmid DNA coding for mIL-12 or dsRed alone (mIL-12, dsRed) or combined with i
(EGT mIL-12, EGT dsRed) or combined with irradiation (EGT mIL-12 + IR, EGT dsRed
N - Number of all mice in the group.
* - Tumor doubling time - only mice with tumors were included in calculation.
** - Tumor growth delay - only mice with tumors were included in calculation.
† - Cures were determined 100 days after the treatment.
# - Resistance to secondary challenge – number of cured mice that were resistant t
‡ - Statistical significant difference compared to control group (p < 0.05).
§ - Statistical significant difference compared to IR (p < 0.05).radiosensitizing effect was also determined for multiple
intratumoral mIL-12 gene electrotransfer in murine
sarcoma.Methods
Animals and tumors
Experiments were performed on A/J mice of both sexes,
12–14 weeks old and weighing 20–25 g. Mice were pur-
chased from the Medical Experimental Centre, Institute of
Pathology, Faculty of Medicine, University of Ljubljana
(Slovenia) and were held at the Institute of Oncology
Ljubljana in a specific-pathogen-free animal colony at
controlled temperature and humidity, with a 12 h light/
dark cycle. Solid SA-1 fibrosarcoma tumors (Jackson
Laboratory, Bar Harbor, ME) were induced in the back of
the syngeneic A/J mice, by subcutaneous injection of 5 ×
105 SA-1 cells [28]. When tumor volumes reached ap-
proximately 40–50 mm3, mice were subjected to a proto-
col specific to each therapeutic group (listed in Tables 1
and 2). The protocols were approved by the Ministry of
Agriculture and Environment of the Republic of Slovenia
(permission no. 34401-10/2009/6).Plasmid DNA
Therapeutic plasmid encoding mIL-12 (pORF-mIL-12,
InvivoGen, Toulouse, France) and control plasmid encod-
ing red fluorescent protein (pORF-dsRed, constructed in
our laboratory) were isolated using a Qiagen Maxi Endo-transfer alone or combined with irradiation on SA-1
GD (days; AM ± SE)** Cures† (%; n) SC resistance#
- 0
2.5 ± 0.6 0
1.3 ± 0.3 0
3.5 ± 0.9 0
1.4 ± 0.4 0
18.3 ± 3.0 7.1 (1/14) 0/1
3.7 ± 0.9 0
12.7 ± 4.2 0
3.6 ± 1.1 0
7.5 ± 1.9 0
8.9 ± 1.7 0
30.9 ± 4.3 § 21.4 (3/14) 1/3
one (EP) or combined with irradiation (EP + IR), intratumoral injection of
rradiation (mIL-12 + IR, dsRed + IR), mIL-12 or dsRed gene electrotransfer alone
+ IR).
o secondary challenge is shown.
Table 2 Antitumor effectiveness of triple mIL-12 gene electrotransfer alone or combined with irradiation on SA-1
sarcoma
Therapeutic group N DT (days; AM ± SE)* GD (days; AM ± SE)** Cures† (%; n) SC resistance (n)#
Control 10 3.4 ± 0.4 - 0
3× EP 10 6.0 ± 1.0 2.7 ± 1.0 0
3× dsRed 10 3.1 ± 0.3 −0.3 ± 0.3 0
3× EGT dsRed 12 6.8 ± 0.8 3.4 ± 0.8 8.3 (1/12) 1/1
3× mIL-12 13 5.2 ± 1.3 1.9 ± 1.3 0
3× EGT mIL-12 14 17.7 ± 5.4 ‡ 14.3 ± 5.4 50.0 (7/14) 7/7
IR 10 Gy 10 8.1 ± 1.5 4.8 ± 1.5 0
3× EP + IR 11 13.1 ± 1.9 9.7 ± 1.9 27.3 (3/11) 3/3
3× dsRed + IR 12 9.9 ± 1.8 6.5 ± 1.8 16.7 (2/12) 2/2
3× EGT dsRed + IR 12 25.7 ± 4.8 ‡§ 22.3 ± 4.8 25.0 (3/12) 3/3
3× mIL-12 + IR 14 10.2 ± 1.7 6.9 ± 1.7 7.1 (1/14) 1/1
3× EGT mIL-12 + IR 15 43.1 ± 28.8 ‡§ 39.8 ± 28.8 ‡ 86.7 (13/15) 13/13
Therapeutic groups: 10 Gy single dose irradiation (IR), triple electric pulse application alone (3× EP) or combined with irradiation (3× EP + IR), triple intratumoral
injection of plasmid DNA coding for mIL-12 or dsRed alone (3× mIL-12, 3x dsRed) or combined with irradiation (3× mIL-12 + IR, 3× dsRed + IR), triple mIL-12 or
dsRed gene electrotransfer alone (3× EGT mIL-12, 3× EGT dsRed) or combined with irradiation (3× EGT mIL-12 + IR, 3× EGT dsRed + IR).
N - Number of all mice in the group.
* - Tumor doubling time - only mice with tumors were included in calculation.
** - Tumor growth delay - only mice with tumors were included in calculation.
† - Cures were determined 100 days after the treatment.
# - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.
‡ - Statistical significant difference compared to control group (p < 0.05).
§ - Statistical significant difference compared to IR 10 Gy (p < 0.05)
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centration of 1 mg/ml.
Gene electrotransfer
Plasmid DNA (20 μl) was injected intratumorally and
10 minutes later 2 sets of 4 electric pulses were applied to
the tumor in perpendicular directions (600 V/cm, 5 ms,
1 Hz). Pulses were delivered with electric pulse generator
GT-01 (Faculty of Electrical Engineering, Ljubljana, Slo-
venia) using stainless steel parallel plate electrodes. The
distance between the electrodes was 6 mm and they were
placed on the skin enclosing the tumor that was approxi-
matelly 5–6 mm long, with approximate height of
2.5 mm. A thin layer of conductive gel was applied on the
sides of the tumor to assure better contact between elec-
trodes and the tumor resulting in only minimal reduction
of the width where the field was delivered [29,30]. After
injection tumors increased in volume, however the swel-
ling rarely exceeded 6 mm, and the tumors could still be
effectively put between the electrodes.
Irradiation of tumors
A Darpac 2000 X-ray unit (Gulmay Medical Ltd.,
Shepperton, UK), operating at 220 kV, 10 mA, with
1.8-mm aluminum filtration, was used for local tumor ir-
radiation. Tumors were irradiated at a dose rate of 2.16 Gy/
min with single doses in a range from 2.5-45 Gy [31]. In
order to expose the whole tumor to the radiation, it wasnecessarily to expose some of the healthy tissue (3 – 5 mm
of skin surrounding the tumor) as well.
Treatment protocol and treatment evaluation
Radiation dose response was determined for graded single
dose tumor irradiation alone (2.5-45 Gy) or combined
with intratumoral mIL-12 gene electrotransfer (2.5-30 Gy)
and 7 – 10 animals per treatment group were used.
Separate experiments were performed combining gene
electrotransfer with 10 Gy tumor irradiation using 9-15
animals per treatment group (Tables 1 and 2). Based on
our previous study [17], gene electrotransfer was per-
formed on day 0 for single, and days 0, 2 and 4 for mul-
tiple treatments and tumors were irradiated on day 1.
The antitumor effectiveness of the therapies was fol-
lowed by measurement of three perpendicular tumor
diameters and calculation of tumor volume using the
formula V = a*b*c*п/6 [32,33]. The tumor growth delay
for each experimental group was calculated as the differ-
ence in tumor doubling times of experimental and con-
trol groups. Tumor doubling time is the number of days
in which the initial tumor volume (40-50 mm3) doubles.
Unpalpable tumors were defined as complete responses.
Mice that remained tumor free for 100 days were termed
cured and local tumor control was deemed to have been
achieved. The tumor control dose (TCD50) value is the
dose required to control 50% of the tumors locally (i.e.
cure 50% of mice). The dose modifying factor is the
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TCD50 by combination therapy compared to irradiation
only. Cured mice (tumor free for 100 days) from experi-
ments listed in Tables 1 and 2 were challenged at day
100 with a subcutaneous injection of 5 × 105 SA-1 cells
into the left flank and monitored for another 100 days.
Animal weight was followed as a measure of the general
index of toxicity.
Cytokine measurements
A new set of experiments was performed in order to
measure the cytokine concentrations in serum and the
tumors. The same treatment groups were used as before
(Table 1) with 8–9 animals per treatment group. Five
days after the start of the therapy, blood was collected
from the intraorbital sinus of all the animals, the animals
were sacrificed, and whole tumors were excised. Tumors
were separated from the skin. Additional experiment
was performed for treatment groups that included the
application of plasmid encoding IL-12 with 6-12 animals
per each time point of individual treatment group. Blood
and tumor samples were collected at days 3, 5, 7, 10 and
14 after the start of therapy.
Tumor and serum samples were stored at −80°C until
further analysis. Tumors were mechanically macerated in
liquid nitrogen, dissolved in 0.5 ml PBS containing prote-
ase inhibitors (Complete Mini, Roche, IN, USA) and cen-
trifuged at 3000 rpm for 10 min [29]. Supernatants were
removed and stored at −80°C until analysis. Tumor and
serum concentrations of cytokines mIL-12 and mIFNγ
were determined using QuantikineW Mouse IL-12 p70
Immunoassay (R&D Systems, MN USA). Concentrations
of cytokines were calculated as pg/ml for serum samples
and pg/g of tumor tissue for tumor samples.
Histological analysis
A new set of experiments was performed in order to
evaluate the histology of tumors in the control group and
after intratumoral mIL12 gene electrotransfer alone or
combined with tumor irradiation. Six mice per treatment
group were sacrificed 5 days after the start of the therapy
and whole tumors were excised and processed as previ-
ously described [17]. Tissue sections stained with
hematoxylin and eosin (H&E) were analyzed by an experi-
enced pathologist to determine changes in tumor cell
morphology, the areal of tumor necrosis and viable part of
the tumor, as well as the inflammatory cell infiltration.
Skin reaction
Acute skin reaction in the whole irradiation field around
the tumor was evaluated in the period from 8 to 58 days
after the irradiation in all mice used for dose response
evaluation. The skin reaction was scored on a scale ran-
ging from 0 to 5 (0 – no reaction, 1 – edema, milderythema, 2 – edema, moderate erythema, dry skin des-
quamation affecting < 20% of irradiated skin; 3 – edema,
severe erythema, dry skin desquamation affecting > 20% of
irradiated skin, 4 – edema, severe erythema, moderate
moist desquamation with ulceration affecting 20-50% of
irradiated skin, 5 – edema, severe erythema, severe moist
desquamation with ulceration affecting > 50% of irradiated
skin) adapted from [31].
Statistical analysis
Sigmaplot 12 software (Systat Software GmbH., San Jose,
California) was used for statistical analysis. All data were
tested with the Kolmogorov-Smirnov test for normality
of distribution. Differences between mean values of ex-
perimental groups were tested with one-way ANOVA,
followed by the Holm Sidak test for multiple compari-
sons. Values of p < 0.05 were considered significant.
Results
Antitumor effectiveness and radiation response after
single mIL-12 gene electrotransfer
Single intratumoral mIL-12 gene electrotransfer in murine
SA-1 sarcoma tumors resulted in 7.1% (1/14) tumor cures
and when combined with tumor irradiation in 21.4%
(3/14) tumor cures. In both treatment groups, a temporary
and transitory increase in the complete response rate was
observed 2-5 weeks after the treatment, reaching 21.4%
after mIL-12 gene electrotransfer alone, and 71.4% after
the combined treatment (Figure 1A). In addition, the
doubling time of the remaining tumors in both treatment
groups was increased significantly (p < 0.05) compared to
untreated tumors (Table 1). Mice cured with the combin-
ation therapy were rechallenged with SA-1 sarcoma cells
100 days after the treatment, and one third of them (1/3)
were resistant to secondary challenge. The mouse that was
cured with single mIL-12 gene electrotransfer alone was
not resistant to secondary challenge.
Tumor irradiation alone or combined with electric
pulse application did not result in tumor cures, however
tumor doubling time was significantly increased after
tumor irradiation combined with electric pulse applica-
tion, compared to the untreated tumors. In other thera-
peutic and control groups presented in Figure 1A and
Table 1, no complete responses and no statistically sig-
nificant change in tumor growth delay compared to un-
treated tumors were observed.
Cytokine levels in tumors and serum
The concentration of mIL-12 and mIFNγ in tumors was
determined in all therapeutic and control groups at day
5 after the start of therapy (Table 3). Significantly ele-
vated concentrations of mIL-12 and mIFNγ (p < 0.05)
were detected in the tumors treated with mIL-12 gene
electrotransfer alone (1027 ± 400 pg/g and 6509 ±
Figure 1 Complete responses of SA-1 tumor bearing mice after combined modality treatment. Single (panel A) and repetitive (panel B)
intratumoral mIL-12 gene electrotransfer was used alone or combined with tumor irradiation. Abbreviations: mIL-12 = intratumoral injection of
plasmid DNA coding for mIL-12; EGT mIL-12 = intratumoral mIL-12 gene electrotransfer; dsRed = intratumoral injection of non-therapeutic plasmid
DNA; EGT dsRed = intratumoral dsRed gene electrotransfer; EP = electric pulse application on the tumors; IR = single dose radiation (10 Gy); All
other groups = other therapeutic groups listed in Tables 1 and 2; 3× = triple therapy. Number of animals per treatment group is listed in Tables 1
and 2.
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radiation (1671 ± 529 pg/g and 7191 ± 1283 pg/g, re-
spectively). Cytokine levels in all other groups (listed in
Table 1) did not exceed 330 pg/g for mIL-12 and
2820 pg/g for mIFNγ. In the serum of the treated ani-
mals, no elevated concentrations of mIL-12 were
detected in any of the therapeutic groups compared to
untreated animals, and mIFNγ concentrations were
below the level of detection (data not shown). In order
to further elaborate the cytokine dynamics, serum and
tumor concentrations of mIL-12 and mIFNγ were mea-
sured at different time points after mIL-12 gene electro-
transfer alone or combined with tumor irradiation
(Figure 2). The intratumoral concentrations peaked forTable 3 Concentration of cytokines in tumors 5 days after
the combined modality treatment
Therapeutic group mIL-12 mIFNγ
Control groups < 330 pg/g < 2820 pg/g
EGT mIL-12 1027 ± 400 pg/g * 6509 ± 1018 pg/g *
EGT mIL-12 + IR 1671 ± 529 pg/g * 7191 ± 1283 pg/g *
Therapeutic groups: mIL-12 gene electrotransfer alone (EGT mIL-12) or
combined with tumor irradiation (EGT mIL-12 + IR). Control groups are
untreated control, 10 Gy single dose irradiation (IR), electrical pulse application
alone (EP) or combined with irradiation (EP + IR), intratumoral injection of
plasmid DNA coding for mIL-12 or dsRed alone (mIL-12, dsRed) or combined
with irradiation (mIL-12 + IR, dsRed + IR), dsRed gene electrotransfer alone (EGT
dsRed) or combined with irradiation (EGT dsRed + IR).
Abbreviations:
mIL-12 – intratumoral levels of mIL-12.
mIFNγ – intratumoral levels of mIFNγ.
* Statistically significant difference compared to untreated control (p < 0.05).
Number of animals in control groups was 8 – 9. Number of animals in groups
EGT mIL-12 and EGT mIL-12 + IR was pooled from two experiments and
was 17–18.mIL-12 and mIFNγ at day 3 post-treatment and within
14 days decreased to pre-treatment levels (Figure 2).
Higher mIL-12 levels (p < 0.05; Figure 2A) were detected
in the combined modality treatment group than in the
mIL-12 gene electrotransfer group; however, no differ-
ence in peak mIFNγ levels was observed (Figure 2B).
Again, no elevated concentrations of mIL-12 were
detected in the serum of the treated animals in any of
the therapeutic groups, even in the first few days after
the start of therapy, and mIFNγ concentrations were
below the level of detection (data not shown).
Histological analysis
Variable tumor areas were seen on histological specimens
at day 5 after intratumoral mIL-12 gene electrotransfer.
The viable tumor area was approximately 50% of the tumor,
whereas it was more than 80% in the control group. Cells
with nuclear polymorphism were seen in this part of the
tumor, as well as some apoptotic cells. Connective tissue in-
growing from the periphery of the tumor was observed and
several inflammatory cells were found there beside fibro-
blasts. Lymphocytes and plasma cells predominated among
inflammatory cells, although some polymorphonuclear
granulocytes were also present (Figure 3A). Some infiltra-
tion of inflammatory mononuclear cells was also found be-
tween tumor cells (Figure 3B).
After mIL-12 gene electrotransfer combined with ir-
radiation, tumors were overall smaller than tumors trea-
ted with mIL-12 gene electrotransfer but the viable
tumor area was almost 90% of the tumor. However, in
contrast to tumors that were treated with mIL-12 gene
electrotransfer only, the cellularity of tumor cells was
Figure 2 Intratumoral concentration of cytokines mIL-12 (panel A) and mIFNγ (panel B). Panel A: * - Statistically significant difference
(p < 0.05) compared to groups mIL-12, mIL-12 + IR. ** - Statistically significant difference (p < 0.05) compared to groups mIL-12, mIL-12 + IR, EGT
mIL-12; Panel B: * - Statistically significant difference (p < 0.05) compared to groups mIL-12, mIL-12 + IR. Number of animals per group was 12
(days 0, 3, 7, 10), 18 (day 5), 6 (day 14).
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(mitotic arrest) were seen (Figure 3C). Infiltration of in-
flammatory cells was also present and consisted mostly
of macrophages, lymphocytes, plasma cells and individ-
ual granulocytes (Figure 3D).Figure 3 Histology of SA-1 tumors. Histology was evaluated at day 5 aft
combined with irradiation (C and D). The arrows show infiltrating immune
P – plasma cells) and giant cells in mitotic arrest (G).Therapeutic index
The benefit of the combined therapy was determined by
TCD50 assay and related to skin reaction in the tumor ir-
radiation field. The TCD50 decreased from 29.8 Gy in
irradiated tumors to 13.8 Gy in tumors that wereer intratumoral mIL-12 gene electrotransfer alone (A and B) or
cells (L – lymphocytes, Gr – granulocytes, M – macrophages,
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electrotransfer (Figure 4A). The dose-modifying factor
of a single mIL-12 gene electrotransfer in murine SA-1
sarcoma was therefore 2.16. At the same level of skin re-
action, dry skin desquamation of less than 20% of irra-
diated skin (score 2), a 44% higher probability of local
tumor control was achieved in combined therapy than
with irradiation alone (Figure 4B).
Animal weight did not significantly change after intra-
tumoral mIL-12 gene electrotransfer alone, or combined
with tumor irradiation, throughout the observation time.
Increase in radiation response after multiple mIL-12 gene
electrotransfer
Multiple intratumoral mIL-12 gene electrotransfer re-
sulted in 50% tumor cures, with a temporary increase of
the complete response percentage up to 57.1% at day 15
(Figure 1B). The combined modality treatment withFigure 4 Therapeutic index. Radiation dose response curves for local tum
B). Arrows indicate response on dry skin desquamation less than 20% (pan
B). In panel A, 7–10 mice per treatment group were evaluated at each dos
each dose and the average of five highest skin reaction scores for each dotumor irradiation resulted in 86.7% tumor cures. The
doubling time of the remaining tumors in both treat-
ment groups was increased significantly (p < 0.05) com-
pared to untreated tumors (Table 2). Cured mice
receiving multiple mIL-12 gene electrotransfer alone
(7/14) or combined with tumor irradiation (13/15)
were resistant to secondary challenge with SA-1 sarcoma
cells (Table 2).
As expected, some of the treatments used as pertinent
controls (Figure 1B, Table 2): multiple electrotransfer of
control plasmid, combination of multiple electric pulse
application and irradiation, as well as multiple injections
or electrotransfer of control plasmid combined with ir-
radiation of tumors, also resulted in tumor cures, but
their antitumor and radiosensitizing effect was less pro-
nounced [34,35]. Furthermore, mice cured with these
treatment modalities were also resistant to the secondary
challenge with SA-1 sarcoma cells (Table 2).or control of SA-1 sarcoma tumors (panel A) and skin reaction (panel
el A), and radiation doses with which this skin reaction occurs (panel
e point. In panel B, 7–10 mice per treatment group were evaluated at
se used was plotted.
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Our study demonstrates that single intratumoral mIL-12
gene electrotransfer resulted in increased intratumoral
but not serum mIL-12 and mIFNγ concentrations, and
induced pronounced antitumor and radiosensitizing
effects in murine SA-1 sarcoma. The combined treat-
ment resulted in a highly increased complete response
rate of tumors and a radiation dose-modifying factor of
2.16. At the same level of skin reaction, dry desquam-
ation, a 44% higher probability of local tumor control
was observed in combined therapy than with irradiation
alone. Multiple mIL-12 gene electrotransfer had even
more pronounced antitumor and radiosensitizing effects.
Several studies have demonstrated that IL-12 is an ef-
fective radiosensitizer; on melanoma, Lewis lung carcin-
oma, mammary carcinoma, squamous cell carcinoma, as
well as on fibrosarcoma, prostate and hepatic cancer
[8,9,11-18]. The potentiation in most studies was additive
or supra-additive, and in several cases also resulted in a
high level of complete responses [8,9,11,17]. In addition to
the use of recombinant IL-12, studies have predominantly
been done with IL-12 gene therapy using viral vectors,
which were injected intratumorally [8,9,11-13]. Intratu-
moral IL-12 gene transfer was also performed in our
study, but using naked plasmid DNA and electric pulse
application as a delivery system. Single mIL-12 gene trans-
fer before tumor irradiation resulted in 21.4% tumor cures,
while an additional two transfections after irradiation con-
tributed to overall response, resulting in 86.7% tumor
cures. The high level of complete responses obtained is
comparable to the study in murine fibrosarcoma AG104A,
in which single intratumoral adenoviral mIL-12 gene
transfer increased the tumor cure rate of fractionated radi-
ation (5 fractions of 5 Gy) from 26% to 59% [9].
Despite the proven efficiency of IL-12 mediated antitu-
mor and radiosensitizing effect, the underlying mechan-
isms of radiosensitization remain to be elucidated, due
to the complex nature of IL-12 signaling and the differ-
ences in effects observed in different tumor models
[20,36]. In previous IL-12 radiosensitization studies, two
main mechanisms have been hypothesized as being re-
sponsible for the effect. The first was improved immune
response to tumor cells based on a significant reduction
of the IL-12 mediated antitumor effect in a T-cell or
NK-cell depleted environment [8] and the development
of antitumor resistance after the combined treatment
modality [9]. A possible explanation is that radiation
induced apoptosis [12] might stimulate the immune re-
sponse by creating more available tumor antigen in the
tumor microenvironment [37]. The second mechanism,
synergistic interaction of the IL-12 anti-angiogenic
effects and radiation was hypothesized as being the main
mechanism in fibrosarcoma tumors, based on decreased
vascularity observed with anti-CD31 staining of tumorsections [9]; the effect, however, was not so prominent
in B-16 melanoma tumors [8].
In our study, we observed increased concentration of
mIL-12 in the tumors after the combined modality treat-
ment with tumor irradiation. Increased production of
IL-12 in the antigen presenting cells has been demon-
strated in whole body irradiated mice [38] however in
the present study tumor irradiation alone did not result
in increased levels of cytokines. Radiation following gene
electrotransfer might increase the production of mIL-12
in the transfected cells (tumor and stromal) however it
might also influence transfection efficiency in a negative
way by damaging or killing a certain percentage of the
transfected cells. However radiation induced cell death
does not necessarily occur immediately and it may take
several days for the cells to die. Results of this and other
studies [17], applying gene transfection prior to radi-
ation, show that the combined modality treatment in
this sequence results in a pronounced radiosensitizing
effect. In the case of immune-modulators the radiosensi-
tization can be temporally separated and still provides
radiosensitization through potentiation of radiation eli-
cited cell damage and by stimulation of the immune
system. The increase in mIL-12 production after the
combined treatment modality could also be due to the
stimulation of IL-12 production in the inflammatory
cells observed in the histological sections of the tumors.
After combined treatment modality presence of several
kinds of immune cells was observed in tumors that were
not present in the control group indicating on infiltra-
tion. In our study the type of lymphocytes was not
identified however previous publications using immuno-
histochemistry have demonstrated presence of both CD4+
and CD8+ T cells in the tumors after intratumoral mIL-12
gene electrotransfer [39]. Infiltration with CD8+ T cells is
necessary for complete tumor eradication and CD4+
T cells help in achieving adaptive immune response
[20,36]. Since in our experiments tumors were successfully
eradicated, and development of anti-tumor resistance was
observed, we can presume that both CD4+ and CD8+ cells
were present. Furthermore, immune cells observed in the
tumors (Figure 3) are known to produce IFNγ upon
stimulation with IL-12, which could explain the elevated
levels of IFNγ, demonstrated after mIL-12 gene electro-
transfer (Figure 2B).
It has been shown that the antitumor effectiveness of
the combined treatment with IL-12 and tumor irradi-
ation depends on the presence of T and NK cells [8],
both of which are stimulated by IL-12. Most of the IL-12
antitumor effects are mediated by the release of IFNγ, al-
though no significant elevation of intratumoral mIFNγ
was observed after combined modality treatment, com-
pared to gene electrotransfer alone, indicating a possible
saturation effect. The better response of the combined
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and anti-angiogenic mechanisms of IL-12, which are in-
dependent of IFNγ [40].
Development of antitumor resistance after the com-
bined treatment modality was also observed in our study
[9]. One of the three tumors cured with single mIL-12
gene electrotransfer combined with tumor irradiation
was resistant to secondary challenge which indicates on
long-term immunity. All the mice cured by multiple
mIL-12 gene electrotransfer alone or combined with ra-
diation were also resistant to secondary challenge, how-
ever the same phenomena was observed with mice
treated with treatments used as pertinent controls (mul-
tiple therapies with electric pulse application or plasmid
coding for dsRed combined with tumor irradiation) that
resulted in tumors cures, due to their immunogenicity.
This indicates that multiple mIL-12 gene electrotransfer
alone or combined with irradiation and also treatments
used as pertinent controls might have either increased
the immunogenicity of SA-1 sarcoma [28,41] (increased
tumor antigen availability after radiation induced apop-
tosis) or stimulated the immune cells (control plasmid
coding for immunogenic protein) [34,42,43] leading to a
better tumor immunosurveillance and prevention of
tumor outgrowth after secondary challenge. Thus, in
contrast to the effects of IL-12 on tumor cures its con-
tribution to the long term immunity could not be
evaluated.
Radiosensitization of sarcomas is relevant in tumors that
exceed the size for therapeutic effectiveness of surgery or
radiotherapy as a sole treatment [25-27]. Intratumoral gene
therapy with IL-12 may in such cases, as demonstrated in
this study, contribute to the antitumor effectiveness of
radiotherapy for effective local tumor control. Importantly,
we demonstrated that skin reaction in the irradiation field
was not increased by combined treatment that resulted in
a dose-modifying factor of 2.16. Intratumoral mIL-12 gene
electrotransfer has already been shown to be effective in
sarcomas; 2.5 times higher mIL-12 plasmid doses (50 μg)
resulted in up to 100% of local tumor control of SA-1 sar-
coma, and also to have a systemic effect on distant tumors,
as demonstrated by prolonged tumor growth delay of un-
treated tumors [28]. Another approach tested for the treat-
ment of sarcomas is multiple intramuscular IL-12
electrotransfer, in which sustained release of IL-12 over
weeks resulted in 30% of tumor cures and an almost 80%
reduction of induced lung metastases [17]. Multiple intra-
muscular mIL-12 gene electrotransfer resulted in a radio-
sensitizing effect, resulting in 44% tumor cures compared
to 28% of tumor cures after mIL-12 gene electrotransfer
only [17]. The results of the present study therefore indi-
cate that intratumoral mIl-12 gene electrotransfer is super-
ior to intramuscular for local tumor control, since multiple
intratumoral mIL-12 gene electrotransfer combined withirradiation resulted in 86.7% tumor cures, while the dose
modifying factor of single intratumoral mIL-12 gene elec-
trotransfer combined with irradiation was 2.16. The result
is also superior to the dose modifying factor that we
obtained in our previous studies on an LPB sarcoma tumor
model [44,45], in which irradiation was combined with
increased chemotherapeutic drug content in the tumors
due to electrotransfer (electrochemotherapy) [46]. In these
studies the dose modifying factor for electrochemotherapy
with cisplatin was 1.6 [44] and for electrochemotherapy
with bleomycin 1.9 [45]. This demonstrates that stimula-
tion of the immune system results in more pronounced
radiosensitization, with broader clinical applicability target-
ing local, but also systemic disease. Our study provides a
proof of concept regarding the therapeutic efficiency of
intratumoral mIL-12 gene electrotransfer combined with
single dose tumor irradiation. However studies using frac-
tionated radiation regime will be necessary in order to
bring this treatment closer to the clinical setting.
Conclusions
Single or multiple intratumoral mIL-12 gene electrotrans-
fer results in increased intratumoral mIL-12 and mIFNγ
cytokine levels, and may provide an efficient treatment
modality for soft tissue sarcoma as a single or adjuvant
therapy to tumor irradiation. Combined treatment resulted
in a highly increased complete response rate of murine
SA-1 sarcoma, with no significant effect on irradiation
induced damage to normal tissue in the irradiation field.
Furthermore, repetitive gene electrotransfer compared to
single one, further potentiated antitumor and radiosensi-
tizing effects as well as increased the resistance to second-
ary challenge.
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